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Summary 
Transgenic mice expressing either the mouse mammary tumor virus (MMTV) superantigen gene 
(sag) alone or in combination with the viral envelope genes (env) (LEL), or all of the viral genes 
(gag, pol,  env,  and sag)  (HYB PKO),  deleted V~14 + T  cells from their immune repertoire. 
However, only LEL or HYB PKO transgenic antigen-presenting  cells were capable of stimulating 
a proliferative  response from nontransgenic primary T  cells or interleukin 2 production from 
a VB15-bearing  T cell hybridoma. These T cell responses could be inhibited by a monospecific 
antibody directed against the MMTV gp52 cell surface glycoprotein. These results indicate that 
the MMTV gp52 gene product participates in the presentation of superantigen to T cells, resulting 
in their stimulation, a requisite step in the MMTV infection pathway. Thus, gp52 could play 
a role in the transfer  of virus between different  subsets of lymphocytes. 
M 
ouse mammary tumor virus (MMTV)  2 is a nonacute 
transforming retrovirus that induces mammary adeno- 
carcinomas in susceptible mice after a relatively long latency 
period (1). MMTV is transmitted by two routes: genetically 
as an endogenous provirus and exogenously as milk-borne 
infectious virus particles. Endogenous MMTV proviruses have 
been found in all commonly used strains of laboratory mice; 
however, the majority of these do not produce functional viral 
particles  capable of being transmitted exogenously (2). 
The MMTV protein products are translated from three 
viral transcripts (3). Two polyproteins are translated from a 
genomic-length KNA (Fig. 1), the 77-kD polyprotein that 
is cleaved to form the viral core proteins and the 180-kD poly- 
protein Pr180g~r~l reverse transcriptase precursor. The 70-kD 
polyproprotein that is processed to form the gp52 and gp36 
envelope (Env) glycoproteins encoded in the 3' half of the 
MMTV genome comes from an internally spliced transcript. 
Because MMTV viral particles are produced by budding, in- 
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z Abbreviations used in  this paper: HYB  PRO,  hybrid  provirus;  LEL, 
LTR/env/LTR; LTK, long terminal repeat;  MMTV, mouse mammary 
tumor virus;  MTV-ORF, mammary tumor virus-open reading  frame; 
NGG, "y-globulin fraction of normal goat  serum. 
fected cells express gp52 and gp36 on their cell membrane 
(4). Gp36 is the transmembrane domain of Env, while the 
cell surface gp52 Env protein on viral particles binds the cel- 
lular receptor for MMTV (5). Finally, a fourth protein product, 
the viral superantigen (Sag), is synthesized from a spliced RNA 
encoded primarily in the two long terminal repeats (LTKs) 
of the provirus. This protein acts as an Mls antigen (for re- 
view, see references 6 and 7) and plays an important role in 
the viral life cycle (8, 9). 
We recently generated C3H/HeN inbred transgenic mice 
that express the C3H exogenous virus sag gene under the 
control of the MMTV LTR (Fig.  1)  (termed MTV-open 
reading frame [OR,  F] transgenic mice) (8). Expression of this 
sag gene resulted in the deletion of cognate Vf114-bearing 
T cells from the immune repertoire of MTV-OKF transgenic 
mice and also protected these animals  from being infected 
by milk-borne exogenous C3H virus. As a consequence, they 
had a much lower incidence and greater latency of MMTV- 
induced tumors (10, 11). 
We show here that although the expression of the sag trans- 
gene caused deletion of cognate T cells in MTV-ORF mice, 
spleen cells from these animals were unable to stimulate an 
Mls response in vitro. In contrast, splenocytes from trans- 
genic mice that contained either an entire provirus, including 
the LTKs, gag, pol,  and env genes (hybrid provirus [HYB 
PRO]) or a deleted provirus that had only the LTKs and env 
genes (LTK/env/LTR [LEL]) stimulated proliferation of pri- 
mary spleen cells and IL-2 production by a V~15-bearing T 
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bodies to the gp52 protein. These results suggest a role for 
the MMTV  cell surface Env protein in Sag presentation. 
Materiah  and Methods 
Plasmids.  The plasmid hybrid MMTV used to make the HYB 
PRO transgenic strain was a gift from G. M. Shackleford, Univer- 
sity of California, Los Angeles (12) (Fig.  1). It contained the 5' 
half of the Mtv-1 endogenous provirus (to the EcoRI site in pol) 
and the 3' half of an integrated copy of C3H exogenous virus (Fig. 
1). The LEL plasmid was constructed by cloning a HindllI-HindIII 
fragment from the hybrid MMTV (containing the emp gene and 
3' LTR) downstream ofa phsmid carrying a LTR from exogenous 
C3H MMTV (Fig. 1). Both inserts used for injection were isolated 
away from vector sequences. 
Generation of Transgenic Mice.  Female  and  male  C3H/HeN 
MTV-, BALB/c,  and SW outbred mice from colonies of germ- 
free-derived, defined-flora  animals were purchased from the Na- 
tional  Institutes  of Health  Frederick  Cancer  Research  Facility 
Frederick, MD. Transgenic mice were produced as previously de- 
scribed  (13); the microinjected C3H/HeN MTV-  fertilized zy- 
gotes were implanted into SW pseudopregnant foster mothers. 
Transgenic  mice were identified by Southern blot analysis (14). 
Cells and FACS  ~ Analysis.  Peripheral blood leukocytes were iso- 
lated as described previously (8). Cells were stained for 45 min at 
4~  with titrated amounts of antibodies (rat anti-CD4 or anti- 
CD8 labeled with phycoerythrin and fluoresceinated rat anti-V~14 
[15] or rat anti-VB6 (PharMingen, Inc., San Diego, CA)], washed 
twice, and analyzed on either a FACScan  |  flowcytometer (Becton 
Dickinson & Co., Mountain View, CA) utilizing FACScan  |  soft- 
ware or on an electronically programmable individual ceil sorter 
(Coulter Electronics Inc., Hialeah, FL). Dead cells were gated out 
by propidium iodide staining. 
RNA Analysis.  RNA was extracted by guanidine thiocyanate 
extraction and CsC1 gradient centrifugation (16). For Northern 
(RNA) blot analysis, equal amounts of RNA were subjected to 
electrophoresis on 0.8%  formaldehyde gels  (17),  transferred to 
nitrocellulose filters, and hybridized with a hbeled mouse cytoskeletal 
B-actin probe (a kind gift from P. Denberg, University of Illinois 
College of Medicine, Chicago, IL). The mouse rRNAs served as 
molecular weight markers. 
For RNase T~ protection analysis, a probe was generated that 
distinguished between transgene transcripts and those of the en- 
dogenous Mtv loci present in the C3H/HeN genome. Because there 
are sequence dissimilarities in the 3' end of viral transcripts derived 
from the endogenous and exogenous viruses (the 3' LTR of aLL the 
transgenes  used came from exogenous C3H MMTV [Fig.  1]), a 
San3A-Sau3A (- 738 bp to - 110 bp) (Fig. 1) fragment from exog- 
enous C3H MMTV was cloned into the BamHI site of pBhescript 
II SK vector (Stratagene,  La Joila, CA) and used to create a probe. 
Labeled RNA probes were synthesized from the vector template 
by using cr  (ICN Biomedical Inc., Irvine, CA) and T3 
RNA polymerase as specified by the supplier (Promega Biotec, 
Madison, WI). An excess of labeled probe ("~5  x  10  s cpm/reac- 
tion) was hybridized to 40 #g of total RNA. Hybridizations were 
performed overnight at 56~  in 30 #1 of hybridization buffer (40 
mM piperazine-N,N'-bis[2-ethanesulfonic acid],  pH 6.4, 0.4 M 
NaCI,  80%  formamide). Approximately 500 U  of RNAase T1 
(GIBCO BILL, Gaithersburg, MD) was added to each reaction in 
a buffer consisting of 0.01 M Tris (pH 7.6), 0.005 M EDTA, and 
0.3 M NaCI and incubated for 1 h at 37~  The protected frag- 
ments were analyzed on 6%  sequencing gels. 
MLC Assays.  Triplicate cultures of 3  x  10  s responder lympho- 
cytes from spleen  or peripheral lymph nodes and  the indicated 
number of mitomycin C-treated stimulator spleen ceLLs were in- 
cubated in a total volume of 200 ~1 of complete medium (Click's 
EHAA medium [GIBCO BILL] supplemented with 5% FCS, 2 
mM t-glutamine, and 5  x  10 -s M B-mercaptoethanol). On day 
4 of culture, 1 #Ci of [3H]thymidine was added and the ceUs were 
harvested 8-10 h later. 
To determine the percent oft ceLLs  responding in the MLC assays, 
2  x  106 mitomycin-treated HYB PRO splenocytes  were cocul- 
tured with 2  x  104 primary T cells isohted from the lymph nodes 
of a nontransgenic C3H/HeN mouse in 2 ml of complete media. 
After 4 d of  culture, the surviving T cells were separated from dead 
ceLLs on Ficoll/Hypaque density gradients, stained with anti-CD4 
and anti-VB14 or anti-VB6  antibodies,  and analyzed by FACS  | 
11,2 Production Assays.  Stimulator spleen cells (10  s) and 5  x 
104 V~15-positive Kox 15-8.3 hybridoma ceils (18) in 200 #1 of 
complete media were cocultured overnight in triplicate. IL-2 produc- 
tion was measured by [~H]thymidine (ICN Biomedicals,  Inc.) in- 
corporation into the IL-2-dependent cell line CTLL-2. 
Western Blot Analysis  and Antibody-blocking  Studies.  MMTV 
virions were purified from C3H/HeN MMTV ~ milk as described 
(19). Viral antigens that were recognized by the polyclonal goat 
anti-MMTV serum as weLL as by the monospecific goat affinity- 
purified anti-gp52 antibody (Quality Biotech Inc., Resource Labo- 
ratory, Camden, NJ) were detected by Western blot analysis. Briefly, 
4 ~g of purified MMTV virus particles  was electrophoresed on 
10% SDS-polyacrylamide gels and dectrotransferred to nitrocellu- 
lose.  The nitroceLLulose strips  were incubated with either anti- 
MMTV (140 #g/ml) or with anti-gp52 antiserum (2 ~g/ml) fol- 
lowed by rabbit anti-goat antiserum (Jackson  ImmunoResearch 
Laboratories,  Inc., West Grove, PA). The rabbit antibodies were 
detected with xzSI-labdcd protein A (ICN Biomedicals,  Inc.). 
For the antibody-blocking studies, the anti-gp52, anti-gp36, and 
anti-p27 antibodies (Quality Biotech Inc., Resource Laboratory), 
as well as ~/-globulin fraction of  normal goat serum (NGG) (Jackson 
ImmunoResearch Laboratories,  Inc.) were dialyzed against 4,000 
vol of PBS overnight at 4~  diluted in complete media at a con- 
centration of 80/~g/ml, and filter steri~zed. MLC assays were per- 
formed in triplicate as described above in the presence of anti-gp52 
antibodies  or NGG at the final concentrations indicated in Fig. 6. 
The percent inhibition was calculated as follows: percent inhibi- 
tion =  [(a  -  b)/a] x 100, where a represents the incorporation in 
the presence of NGG and b represents the incorporation in the pres- 
ence of the same concentration of anti-gp52 antibody. 
For the preadsorption of the anti-gp52 antibody, "~107 spleno- 
cytes from nontransgenic C3H/HeN or transgenic HYB PRO mice 
per microgram of antibody were incubated for 1 h at room tem- 
perature, followed by 1 h at 4~  The cells were peLLeted  and the 
supernatant used in blocking experiments as described above. 
Results and Discussion 
In addition to the MTV-ORF  transgene previously de- 
scribed (8), we used two constructs to create transgenic mice 
in the C3H/HeN  inbred background.  One strain,  termed 
HYB PRO (12), contained as a transgone an entire copy of 
a genetically engineered MMTV provirus in which  the 3' 
half (including 3' LTR, env, and sag genes) was derived from 
C3H exogenous virus and the 5' half (including 5' LTR, gag, 
and pol genes) came from the Mtv-1 endogenous locus al- 
ready present in C3H/HeN  mice (Fig. 1). The second con- 
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Figure  1.  Diagram  of the HYB PRO, LEL, and MTV-ORF  tramgenes. 
(l~p) HYB PRO transgene and the three transcripts generated from this 
provirus, including the viral protein coding regions. The LEL construct 
was cloned as described  in Materials and Methods; only one RNA coding 
for both the env and sag genes can be transcribed. (Bottom) MTV-ORF 
transgene and transcript. The filled  box represents the region of the LTR 
used as a probe for RNase T1 protection analysis. H, HindlII; R, EcoRI; 
$, Sau3A. 
struct used to microinject embryos, LEL, had a deletion of 
all of the gag and most of the pol coding regions, but re- 
tained the env gene as well as the 5' and 3' LTRs from C3H 
exogenous virus (Fig. 1). One strain of HYB PRO mice and 
two independently derived strains  of LEL mice were used 
in these strains. 
The presence of a self sag gene or Mls locus in mice is 
characterized by the absence of mature T cells bearing receptors 
encoded by a particular Vfl gene segment (20-23). To deter- 
mine whether the HYB PRO and LEL transgenic mice pro- 
duced functional Sag protein,  the percentage of V~14 + T 
lymphocytes present in their periphery was measured. Similar 
to what was seen with MTV-ORF transgenic mice, the HYB 
PRO as well as LEL mice showed specific deletion of both 
CD4+/VB14 + and CD8+/VB14 + T  cells (Table 1). Thus, 
all three types of transgenic mice, MTV-ORF, LEL, and HYB 
PRO, demonstrated one of the characteristics  of Mls (in other 
words,  they deleted cognate T  cells). 
The Mls genes were originally named for their ability to 
stimulate the proliferation of specific V~-bearing T  cells in 
MLC assays of spleen cells isolated from mouse strains iden- 
tical at the MHC (24). We therefore determined if primary 
spleen cells from these different transgenic mice could present 
the Sag protein in in vitro MLC assays. Primary spleen cells 
from MTV-OtLF, LEL, and HYB PRO transgenic mice were 
tested  for  their  ability  to  stimulate  the  proliferation  of 
C3H/HeN  MMTV-  nontransgenic  primary lymph  node 
cells or splenocytes. No splenocytes isolated from any of the 
three different strains of MTV-ORF transgenic mice tested 
(nos.  13,  16, and 35; reference 8) could stimulate prolifera- 
tion of the nontransgenic responder cells (Fig. 2 A). Moreover, 
even after activation with LPS, the MTV-OILF splenocytes 
did not stimulate the responder cells (not shown).  In con- 
trast, spleen cells from both the HYB PRO and LEL trans- 
genic mice caused proliferation of these same responder cells 
(Fig. 2 A), and LPS blasts prepared from these mice caused 
even higher stimulation than primary splenocytes (not shown). 
The HYB PRO splenocytes stimulated the responder cells 
*2-fold more than those isolated from either strain of LEL 
mice, which was probably a reflection of the higher level of 
transgene  expression (see below). 
To ensure that the proliferative response was directed against 
the Sag protein encoded in the LTK, we first tested whether 
the VfllS-bearing hybridoma cell line Kox 15-8.3 (18), which 
recognizes the C3H MMTV Sag,  responded to the trans- 
genic APCs.  We have previously shown that  only hybrid- 
omas bearing Vf114 or VB15 TCKs were stimulated by HYB 
PRO APCs (10). The Kox 15-8.3 cells produced IL-2 when 
stimulated with primary splenocytes from both the HYB PRO 
and  LEL,  but  not  MTV-OKF  transgenic  mice  (Fig.  3), 
showing that  the Sag protein was presented to cognate T 
Table  1.  Deletion of V~14  T  Cells in MTV-ORF, HYB PRO, and LEL  Transgenic Mice 
T  cells bearing  V~14" 
Mice  Transgene  RNA level  CD4/Vf114  CD8/V/314 
% 
C3H/HeN MTV-  N.A.  8.2  +_  1.1  9.5  •  1.3 
MTV-ORF  13  High  2.1  +  0.2  2.3  +  0.4 
MTV-O1LF 16  High  1.2  •  0.2  2.4  •  0.4 
MTV-ORF 35  High  1.8  +_ 0.4  2.3  •  0.2 
HYB PRO  High  0.8  •  0.4  1.6  •  0.8 
LEL 1  Low  1.5  _+ 0.2  3.2  •  0.2 
LEL 2  Low  2.0  _+ 0.5  3.3  •  0.2 
* T cells were isolated from the peripheral blood or lymph nodes of the mice indicated and analyzed for the percentage of CD4- or CD8-bearing 
Vf114  + T cells. The numbers shown represent the average of between three and six experiments. N.A.,  not applicable. 
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IL-2 prodaction by the V~15-bearing hybridoma Kox 15-8.3 
in response to LEL, HYB PRO, and MTV-ORF APCs. Fox 15-8.3 cells 
were stimulated with splenocytes  isolated from the strains of mice indi- 
cated. Presented are the results obtained with one MTV-OR.F strain (No. 
16); all three strains were tested and none were able to stimulate the Kox 
15-8.3 hybridomas (not shown). 
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Figure 2.  Response of nontransgenic and transgenic T cells to MTV- 
OKF, LEL, and HYB PRO APCs. (A) T cells were purified from the 
lymph nodes of C3H/HeN nontnmgenic mice and used as responder  cells 
for MI.C experiments. Stimulator cells were isolated from the spleens of 
the age-matched mice of the indicated strains. 5  x  10  s stimulator cells 
were used in these experiments. The results shown are representative of 
2 of the 12 independent  experiments  performed. (B) Splenocytes  from LEL 
and MTV-ORF transgenic  mice were used as responder  cells in MLC assays 
performed with APCs (5 x  10  s stimulator cells) isolated  from the spleens 
of LEL, MTV-ORF, HYB PRO transgenic, and C3H/HeN and BALB/c 
(ALLO response) nontransgenic mice. Shown are the results of one of 
four experiments. 
cells. Thus, even with a sensitive hybridoma, no Sag activity 
was observable with MTV-OILF stimulators. We also deter- 
mined whether there was proliferation of V~14-bearing pri- 
mary T cells when nontransgenic OH/HeN  splenocytes were 
used as responders to HYB PKO splenocytes in MI.C assays. 
Approximately 8--10% of the CD4 + T  cells in C3H/HeN 
mice contain the V//14 TCK (Table 2 and reference 8); after 
stimulation with the HYB PRO splenocytes' however, 35% 
of the proliferating CD4 + T  cells were V814 + . In contrast, 
T  cells bearing th  e Vfl6 TCR did not proliferate in response 
to the HYB PKO-presenting  cells (Table 2). 
To determine whether the HYB PKO APCs expressed mol- 
ecules other than the MMTV Sag that could stimulate T cells, 
lymph node cells from the MTV-ORF and LEL mice were 
tested for their response to HYB PRO splenocytes (Fig. 2 
B). Although  the MTV-ORF  and LEL T  cells responded 
to allogeneic BALB/c stimulators,  they did not respond to 
the HYB PKO cells. Therefore, even though their spleen cells 
did not  stimulate  nontransgenic  C3H  responder cells,  the 
MTV-OILF mice were functionally tolerant to the MMTV 
Sag. This agrees with other studies showing a lower threshold 
for tolerance or deletion than for stimulation (25, 26). These 
data, taken together with those in Fig. 3, demonstrate that 
all of the proliferative response of C3H T  cells to LEL or 
HYB PRO  APCs was due to Sag recognition. 
One possible explanation for the ability of the LEL and 
HYB PRO splenocytes to present Sag was that the env se- 
quences in these transgenes caused upregulation of sag tran- 
scription in these cells relative to the MTV-OR.F APCs. To 
Table  2.  V~14 + Primary T  Cells Proliferate in Response to 
HYB PRO  Transgenic Splenocytes 
T  cells bearing V~14 or V~6* 
CD4/VB14  CD4/VB6 
% 
Before stimulation  7.5  9.2 
After stimulation  35.3  0.82 
* T  cells were isolated from the  lymph nodes of the  nontransgenic 
C3H/HeN  mouse and  analyzed by  FACS  ~  for  the  percentage of 
CD4/Vf114 or CD/Vfl6 before or after stimulation with the splenocytes 
isolated from a HYB PRO transgenic mouse. The percentage of CD4 § 
T cells  ~that are V814 § or V/~6  + are shown. The data from one of two 
experiments are shown. 
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a specific probe that distinguished between the 3' end of the 
HYB PRO, LEL, and MTV-ORF and endogenous MMTV 
transcripts  (Fig.  1)  was  used  for  RNAase  T1  protection 
assays. These assays were performed with RNA isolated from 
the salivary gland of the transgenic strains, since this organ 
contains very high levels of both endogenous MMTV and 
MMTV LTR-directed tramgene RNA (27). The level  of trans- 
gene RNA in the HYB PRO transgenic mice was approxi- 
mately equal to the MTV-ORF transgenic mice (Fig. 4, com- 
pare lanes I  and 2 to lane 3). Similar results were obtained 
with RNA isolated from spleen and other tissues (data not 
shown). Moreover, although both strains of LEL transgenic 
mice deleted their Vf114  + T cells in vivo and presented the 
Sag protein in vitro, transgene-specific RNA was not detect- 
able in either strain, indicating that both strains of LEL mice 
expressed very low levels (Fig.  4, lanes 4 and 5). We have 
been able to detect expression of the LEL transgene only in 
the lactating mammary gland of these mice (not shown). 
The MTV-ORF mice most likely expressed the highest 
levels of the sag-specific  transcript, since all of the transgene 
RNA detected in this assay codes for this gene (Fig.  1). In 
contrast, only one of the three possible viral transcripts pro- 
duced in the HYB PRO mice encoded the sag gene product 
(the probe used detected the 3' end of all three viral RNAs: 
gal/pol,  env,  and sag)  (Fig.  1). Thus, the ability of spleno- 
cytes from the MTV-ORF mice to present the C3H Sag was 
not related to the level of transgene transcription, although 
we cannot rule out that the level of functional protein ex- 
pressed is lower in these mice than in the HYB PRO and 
LEL  mice (see below). 
These data suggested that there was a contribution to Sag 
presentation by other genes encoded in the MMTV genome. 
Since the only difference between the MTV-ORF mice that 
was shared by the HYB PRO and LEL mice was the pres- 
ence of the C3H exogenous virus env genes (the gag and pol 
genes were derived from the Mtv-1 endogenous provirus al- 
Figure  4.  The  level  of  the 
transgene RNA in HYB PRO, 
MTV-ORF,  and  LEL  mice. 
RNase T1 protection analysis of 
RNA isolated from the salivary 
glands of age-matched males  of 
the indicated strains was perfor- 
med. The labeled probe used for 
this  analysis  is  described  in 
Materials and Methods and Fig. 
1. Lane I, MTV-ORF no. 16; lane 
2,  MTV-ORF  no.  35;  lane 3, 
HYB PRO;  lane 4, LEL no.  1; 
hne 5, LEL no. 2; lane 6, C3H/ 
HeN nontramgenic; lane 7, yeast 
tRNA.  The bottom panel con- 
rains  10 gg of each  RNA  sub- 
jeered to Northern blot analysis 
and  hybridized  to  the  mouse 
cyto~alml  B-act-in  probe,  t, u-~ns- 
gene; p, probe. 
Figure  5.  Western blot anal- 
),sis of the anti-gp52 antiserum 
with purified MMTV viriom. Ex- 
ogenous  MMTV  was  purified 
from  milk  of  C3H/HeN 
MMTV +  females  and  analyzed 
by Western blot analysis using ei- 
ther anti-MMTV serum, which 
detects the major vital capsid pro- 
teins (gp52, gp36, p27, and p14) 
or the affinity purified anti-gp52 
monospecitic antibody, which de- 
tects only the gp52 protein. 
ready found in C3H/HeN mice), our results suggested that 
the gp52 or gp36 proteins were involved in the processing 
or presentation of the Sag protein. Because gp52 is the major 
viral cell surface protein found on infected cells (3), we tested 
whether it was participating in the Sag stimulation of cog- 
hate T cells  by adding monospecific anfi-C3H exogenous virus- 
gp52 affinity-purified  polyclonal antibody (Fig.  5) to MLC 
assays in which either LEL or HYB PRO splenocytes were 
used as APCs. At the highest concentration used, this anti- 
body suppressed by 50-75% the response of nontransgenic 
responder cells to either LEL or HYB PRO APCs and the 
level of inhibition was proportional to the amount of anti- 
body present in the assay (Fig. 6, A  and B), indicating that 
gp52 was involved in Sag presentation. 
In contrast to the effect seen with the anti-gp52 antibody, 
neither NGG (Fig. 6 A) nor monospecific antibody directed 
against the MMTV gp36 Env or p27 virion core proteins 
(not shown) inhibited the response to LEL or HYB PRO 
APCs. Moreover,  the anti-gp52 antibody did not block the 
allogeneic response of C3H T  cells to BALB/c splenocytes 
(Fig.  6 B), showing that the inhibition was specific to the 
Sag response. Preadsorption of the anti-gp52 antibody with 
nontransgenic C3H/HeN spleen cells did not affect its ability 
to block Sag recognition by T  cells, whereas preincubation 
with HYB PRO spleen cells completely removed this effect 
(Fig. 6 C). Thus, the antibody inhibition of the Mls response 
was specific to recognition of exogenous MMTV gp52 pro- 
tein and not due to interaction of the antibody with normal 
T  cell or APC cell surface proteins. 
There are several possible ways in which the gp52 protein 
could contribute to the T cell response to the MMTV Sag. 
Since gp52 is a cell membrane protein, it could interact with 
the Sag protein and be involved in its transport to the sur- 
face. If the gp52 protein were involved in transport, how- 
ever, it is unlikely that the anti-gp52 polyclonal antiserum 
would block the T cell response. Alternatively, the Env pro- 
tein could stabilize cell surface Sag protein expression and 
decrease its turnover or it could stabilize a Sag/MHC class 
II complex. We cannot directly address these possibilities, 
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Figure  6.  Inhibition  of the Mls response by anti-gp52 antibody. (.4) 
Kesponder T cells from the lymph nodes of C3H/HeN nontransgenic 
mice were stimulated  with 5 x  10  s spleen cells from LEL no. 1 in the 
presence of the indicated  concentrations  of NGG or anti-g-p52 antibodies. 
The results of one of three experiments are shown. (B) T cells isolated 
from the lymph  nodes of C3H/HeN nontransgenic  mice  were stimulated 
with 5 x  10  s LEL no. 1, 2 x 10  s HYB PRO, or 10  s BALB/c  (ALLO) 
spleen cells in the presence of the indicated  concentrations  of anti-gp52 
antibody or NGG and the percent inhibition  was calculated  as described 
in Materials  and Methods, The mean and SEM of three experiments for 
the LEL and BALB/c  mice  are shown; one experiment  for the HYB PRO 
mouse is shown. (C) T cells from the lymph nodes of C3H/HeN non- 
transgenic mice were stimuhted  with 5 x 10  s spleen cells from  LEL no. 
1 in the presence of the indicated  concentrations  of anti-gp52 antibody 
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since there are no immunological reagents for the C3H ex- 
ogenous Sag protein available that would allow measurement 
of cell surface levels, as has been done for endogenous Sags 
(28-30).  However, because of the extremely low levels of Sag- 
encoding RNA in the LEL mice, whose APCs can induce 
a T  cell response,  relative  to the MTV-ORF mice, whose 
APCs cannot, it seems unlikely that there was more Sag pro- 
tein expressed in the former. All of these models could result 
in an increased density of the Sag ligand to levels that acti- 
vate T  cells. 
Another possibility is that the gp52 protein functions as 
a costimulatory signal. It is now known that T cell receptor 
recognition of conventional antigen peptides alone does not 
provide sufficient stimulus to induce a T  cell-mediated im- 
mune response  and that additional cell-ceU interactions be- 
tween activated T  cells and APCs are required (31). Such 
stimuli are provided by the interaction of APC molecules such 
as B7 with the CD28 receptor found on the T  cell surface 
(32) and heat-stable antigen and its unknown receptor (33). 
Costimulation through these molecules leads  to enhanced 
cytokine production by primary T cells and the subsequent 
proliferation of both T and B cells. Since the gp52 Env pro- 
tein is found on the membrane of infected cells (4), it is pos- 
sible that it could provide a costimulatory signal during Sag 
presentation by interacting with a molecule expressed on the 
responding primary T cells or hybridomas. If gp52 does par- 
ticipate in the Mls response in this manner, our results indi- 
cate that there are different requirements for the presentation 
of Sag and conventional antigens to T cell hybridomas, since 
the latter are thought not to require costimulatory signals (34). 
In contrast to the results presented here, a number of in- 
vestigators have shown that the sag gene alone transfected 
into APCs, such as immortalized B cell lines,  is presented 
to T cell hybridomas expressing suitable receptors  (35-37). 
There are several possible reasons for this discrepancy. First, 
in the transfection experiments, strong promoter/enhancer 
regions from either cytomegalovirus or the B-acdn gene were 
used to drive sag expression and the level of antigen presented 
in transfected cells may be much greater than in primary 
splenocytes (28). Second, the APCs used in the transfection 
assays contain several endogenous MMTVs that are expressed 
and could have functional env genes that complement the trans- 
fected sag gene. It is interesting to note, one group has reported 
complementation of presentation of a transfected sag gene 
by a coexpressed env gene when the Moloney routine leukemia 
virus LTR was used to direct expression  (36). 
These results show that although the sag gene product alone 
is able to cause the specific deletion of VB14 + T  cells and 
the induction of tolerance in vivo, it is not sufficient to in- 
duce the Mls response  in vitro. Interestingly, although the 
LEL mice expressed the lowest transgene levels, they had ap- 
proximately the same level of V/314 +-T cell deletion as the 
HYB PRO and MTV-OILF mice (Table 1). We have previ- 
ously shown that the level of cognate T  cell deletion was 
(gp52) or gp52 antibody preabsorbed with nontransgenic (gp52 [C3H/ 
HEN]) or HYB PRO transgenic (gp52 [HYB PRO])  sphnocytes. The 
results of one of two experiments are shown. 
env  Gene and Mls proportional to the level of  sag transcription among different 
MTV-OKF mice (8). It appears,  therefore, that the presence 
of  Env may also result in better Sag presentation and cognate 
T  cell ddetion in vivo, as well as in in vitro MLC assays. 
It has recently been shown that B cells can be infected by 
MMTV and can transfer virus to T  cells (38). The cell sur- 
face of such B cells or other APCs must therefore contain 
the protein products of both the sag and env genes.  The use 
of the Env protein as an additional signal by infected APCs 
could lead to greater stimulation of  responding cells and greater 
levels of infection. This mechanism of stimulation of T cells 
by MMTV-infected APCs may have evolved as an efficient 
mech~,ism for transferring virus, especially at the early stages 
of infi~on when the total number of  infected cells is very low. 
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